# A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

Source: https://onco.cc/trials/nct06500676/  
OnCo record `nct06500676` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GFH375 in advanced solid tumours, run by Genfleet Therapeutics (Shanghai) Inc., now recruiting.

## Summary

A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations is a phase 1/2 interventional study registered as NCT06500676 by Genfleet Therapeutics (Shanghai) Inc., with 407 participants planned, started 2024-07-09 and due to reach its primary completion in 2028-07-31. Interventions recorded: GFH375.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06500676
- Phase: 1/2
- Setting: An Open-Label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GFH375 in Patients With KRAS G12D Mutant Advanced Solid Tumors
- Sponsor: Genfleet Therapeutics (Shanghai) Inc.
- Enrolled: 407

## Sources

- ClinicalTrials.gov NCT06500676: https://clinicaltrials.gov/study/NCT06500676

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [GFH375](https://onco.cc/drugs/gfh375/)

---
JSON: https://onco.cc/api/v1/entities/nct06500676.json